IL227747A0 - Combinations comprising macitentan for the treatment of glioblastoma multiforme - Google Patents

Combinations comprising macitentan for the treatment of glioblastoma multiforme

Info

Publication number
IL227747A0
IL227747A0 IL227747A IL22774713A IL227747A0 IL 227747 A0 IL227747 A0 IL 227747A0 IL 227747 A IL227747 A IL 227747A IL 22774713 A IL22774713 A IL 22774713A IL 227747 A0 IL227747 A0 IL 227747A0
Authority
IL
Israel
Prior art keywords
mesitantan
treatment
glioblastoma multiforme
combinations containing
combinations
Prior art date
Application number
IL227747A
Other languages
English (en)
Hebrew (he)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45787254&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL227747(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of IL227747A0 publication Critical patent/IL227747A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL227747A 2011-02-04 2013-08-01 Combinations comprising macitentan for the treatment of glioblastoma multiforme IL227747A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2011050494 2011-02-04
PCT/IB2012/050513 WO2012104822A1 (en) 2011-02-04 2012-02-03 Combinations comprising macitentan for the treatment of glioblastoma multiforme

Publications (1)

Publication Number Publication Date
IL227747A0 true IL227747A0 (en) 2013-09-30

Family

ID=45787254

Family Applications (1)

Application Number Title Priority Date Filing Date
IL227747A IL227747A0 (en) 2011-02-04 2013-08-01 Combinations comprising macitentan for the treatment of glioblastoma multiforme

Country Status (21)

Country Link
US (1) US20130310407A1 (enExample)
EP (2) EP2965757A1 (enExample)
JP (2) JP5642892B2 (enExample)
KR (1) KR101563069B1 (enExample)
CN (1) CN103327975A (enExample)
AR (1) AR085132A1 (enExample)
AU (1) AU2012213036A1 (enExample)
BR (1) BR112013019680A2 (enExample)
CA (1) CA2823994A1 (enExample)
CL (1) CL2013002193A1 (enExample)
CO (1) CO6761366A2 (enExample)
EA (1) EA201391131A1 (enExample)
IL (1) IL227747A0 (enExample)
MA (1) MA34952B1 (enExample)
MX (1) MX2013008798A (enExample)
PH (1) PH12013501461A1 (enExample)
SG (1) SG192600A1 (enExample)
TN (1) TN2013000333A1 (enExample)
TW (1) TW201309298A (enExample)
WO (1) WO2012104822A1 (enExample)
ZA (1) ZA201306613B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
EP2464218B1 (en) 2009-08-10 2015-05-27 Board of Regents, The University of Texas System Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent
CN103397308A (zh) * 2013-08-01 2013-11-20 光垒光电科技（上海）有限公司 用于mocvd设备的喷淋头
TWI559928B (en) * 2014-08-20 2016-12-01 Academia Sinica Methods for enhancing permeability to blood-brain barrier and uses thereof
KR101701619B1 (ko) 2015-06-26 2017-02-01 건양대학교산학협력단 뇌교종 세포 치료를 위한 테모졸로마이드와 비타민 d가 포함된 조성물
KR102574253B1 (ko) 2020-12-15 2023-09-07 주식회사 시선테라퓨틱스 펩티드 핵산 복합체를 유효성분으로 함유하는 교모세포종 예방 또는 치료용 조성물
CN115317604B (zh) * 2022-08-11 2023-09-22 南京脑科医院 一种靶向胶质瘤的共载放疗增敏阳离子纳米制剂及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053557A1 (en) 2000-12-18 2002-07-11 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
WO2008111092A1 (en) * 2007-03-09 2008-09-18 Fresenius Kabi Oncology Limited Crystalline temozolomide monohydrate and process for preparation thereof
CN101939001B (zh) 2008-02-20 2012-06-20 埃科特莱茵药品有限公司 用于治疗卵巢癌的含有紫杉醇的组合
EP2464218B1 (en) * 2009-08-10 2015-05-27 Board of Regents, The University of Texas System Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent

Also Published As

Publication number Publication date
ZA201306613B (en) 2015-04-29
PH12013501461A1 (en) 2019-03-22
SG192600A1 (en) 2013-09-30
KR20130118981A (ko) 2013-10-30
JP2014504636A (ja) 2014-02-24
EP2670405B1 (en) 2015-09-02
MA34952B1 (fr) 2014-03-01
CO6761366A2 (es) 2013-09-30
NZ615005A (en) 2015-10-30
CL2013002193A1 (es) 2014-05-09
TN2013000333A1 (en) 2015-01-20
JP5642892B2 (ja) 2014-12-17
JP2015057409A (ja) 2015-03-26
BR112013019680A2 (pt) 2016-10-11
AR085132A1 (es) 2013-09-11
CN103327975A (zh) 2013-09-25
CA2823994A1 (en) 2012-08-09
AU2012213036A1 (en) 2013-09-19
EA201391131A1 (ru) 2013-12-30
US20130310407A1 (en) 2013-11-21
EP2965757A1 (en) 2016-01-13
WO2012104822A1 (en) 2012-08-09
EP2670405A1 (en) 2013-12-11
KR101563069B1 (ko) 2015-10-23
MX2013008798A (es) 2013-10-17
TW201309298A (zh) 2013-03-01

Similar Documents

Publication Publication Date Title
LTPA2020510I1 (lt) Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
EP2663304A4 (en) COMBINATION THERAPY
PL2544682T3 (pl) Fitokannabinoidy w leczeniu glejaka
BR112013032887A2 (pt) cateter
EP4144845C0 (en) ANTISENSE COMPOUNDS AND THEIR USES
IL230657A0 (en) Compounds for the treatment of addiction
EP2692380A4 (en) SYRINGE
HUE043171T2 (hu) Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
LT2707030T (lt) Vėžio gydymas
IL231351A0 (en) Amino-substituted imidazopyridazines
HUE046667T2 (hu) Rák kombinatív kezelése
DK2760886T3 (da) Immunocytokin-kombinationsterapi
EP2726095A4 (en) COMBINATION THERAPY
FI20115876A0 (fi) Yhdistelmähoito
DK2489413T5 (da) Behandlingsapparat
IL231092A0 (en) Treatment of rhinitis
PT2750709T (pt) Tratamento da caquexia
EP2783256A4 (en) Therapeutic eyewear
IL229081A0 (en) Isoxazolines as therapeutic agents
EP2769718A4 (en) MEDICAL COMPOSITION
LT2812013T (lt) Kompozicija, skirta džs gydymui
ZA201306613B (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
BR112013023539A2 (pt) derivados de isoxazolidina
CO6880064A2 (es) Métodos terapéuticos
FI20115640A0 (fi) Yhdistelmähoito